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Diagnosing a periprosthetic joint infection (PJI) can be a clini-
cal challenge, especially for chronic and low-grade infections. 
The preoperative diagnostic work-up, e.g. serum C-reactive 
protein (CRP), erythrocyte sedimentation rate (ESR), synovial 
culture, and several synovial biomarkers can be false negative 
or false positive (Hozack et al. 1991, Ivanèeviae et al. 2002, 
Koh et al. 2017). The currently applied diagnostic criteria as 
described by the Musculoskeletal Infection Society (MSIS) to 
diagnose a PJI do not entail advanced nuclear imaging  (Parvizi 
et al. 2011). However, given the difficulty of the diagnosis of 
PJI and the rapidly evolving field of nuclear diagnostics, it 
may be beneficial to add this technology to the diagnostic pos-
sibilities.
Several nuclear medicine imaging techniques are available 
to assist in diagnosing or excluding PJI, but the choice of 
which technique to use first depends mostly on local expertise, 
availability of techniques, and costs. The labelled white blood 
cell (WBC) scintigraphy is currently considered as the gold 
standard, because of its high specificity for infection (Jutte et 
al. 2014) but has its limitations. The technique is time-con-
suming for both patient and personnel, is not available in all 
hospitals, and patients with leukopenia are not suitable for the 
test due to a low labelling efficacy (Glaudemans et al. 2013, 
Palestro 2015).
A good alternative for WBC scintigraphy could be 18F-flu-
orodeoxyglucose positron emission tomography (FDG-PET), 
which can be combined with computed tomography (CT) for 
exact anatomical localization (the CT part) of the accumu-
lation of FDG (Boellaard et al. 2015). FDG-PET is widely 
available, more comfortable for the patient, provides better 
possibilities for quantification, and results in higher resolu-
tion images compared with WBC scintigraphy (Love et al. 
2005, Verberne et al. 2016). However, an important limitation 
Background and purpose — 18F-fluorodeoxyglucose 
positron emission tomography (FDG-PET) can be used in 
the diagnostic work-up of a patient with suspected peri-
prosthetic joint infection (PJI) but, due to a lack of accurate 
interpretation criteria, this technique is not routinely applied. 
Since the physiological uptake pattern of FDG around a joint 
prosthesis is not fully elucidated, we determined the physi-
ological FDG uptake in non-infected total hip prostheses.
Patients and methods — Patients treated with pri-
mary total hip arthroplasty (1995–2016) who underwent a 
FDG-PET/CT for an indication other than a suspected PJI 
were retrospectively evaluated. Scans were both visually 
and quantitatively analyzed. Semi-quantitative analysis was 
performed by calculating maximum and peak standardized 
uptake values (SUVmax and SUVpeak) by volume of interests 
(VOIs) at 8 different locations around the prosthesis.
Results — 58 scans from 30 patients were analyzed. In 
most hips, a diffuse heterogeneous uptake pattern around the 
prosthesis was observed (in 32/38 of the cemented prosthe-
ses, and in 16/20 of the uncemented prostheses) and most 
uptake was located around the neck of the prosthesis. The 
median SUVmax in the cemented group was 2.66 (95% CI 
2.51–3.10) and in the uncemented group 2.87 (CI 2.65–4.63) 
(Median difference = –0.36 [CI –1.2 to 0.34]). In unce-
mented prostheses, there was a positive correlation in time 
between the age of the prosthesis and the FDG uptake (rs = 
0.63 [CI 0.26–0.84]).
Interpretation — Our study provides key data to develop 
accurate interpretation criteria to differentiate between phys-
iological uptake and infection in patients with a prosthetic 
joint.
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of FDG-PET/CT when compared with WBC scintigraphy is 
its lack of discrimination between infection and inflammation 
secondary to a physiological reaction to the foreign body (the 
implant). In addition, it is not known how long physiological 
FDG uptake around a prosthesis remains after primary arthro-
plasty (Delank et al. 2006, Glaudemans et al. 2013). Conse-
quently, diagnostic interpretation criteria for declaring an 
FDG-PET/CT positive or negative for PJI are lacking and, as a 
consequence, FDG-PET/CT is not routinely performed for the 
diagnosis of PJI. Therefore, we determined the physiological 
FDG uptake in non-infected total hip prostheses. 
Patients and methods
Patients
Data of patients who underwent a primary total hip arthroplasty 
between January 1995 and December 2016 and underwent an 
FDG-PET/CT scan in the time period after the primary arthro-
plasty for reasons other than a suspected PJI (mostly for onco-
logical reasons) were collected retrospectively. Patients were 
included only if they had no clinical signs (e.g., pain at rest) of 
a PJI at the time the FDG-PET/CT scan was performed. The 
included patients were divided into 2 groups, cemented and 
uncemented.
FDG-PET/CT imaging
All FDG-PET/CT scans were performed with an EARL 
accredited scanner, Siemens Biograph MCT 64 or 40 slice 
(Knoxville, TN, USA). Patients were instructed to fast for at 
least 6 hours prior to the administration of FDG. Blood glu-
cose levels were measured before injection of the FDG and 
had to be below 11 mmol/L. The acquisition of the scan started 
after a resting time of approximately 60 minutes after 3 MBq/
kg FDG administration. All scan acquisition parameters were 
according to existing guidelines from the European Associa-
tion of Nuclear Medicine (EANM) (Boellaard et al. 2015). All 
analyses were performed on EARL reconstructed images. 
Image interpretation and analysis 
Both visual and semi-quantitative analysis was performed to 
evaluate the FDG uptake surrounding the prosthesis. For the 
visual analysis, FDG uptake was categorized in 4 categories: 
diffuse heterogeneous (uptake around the prosthesis with dif-
ferent intensities), diffuse homogeneous (relative constant 
uptake around the prosthesis), focal (1 spot with high inten-
sity), and no uptake. In addition, when there was extension of 
FDG uptake in the soft tissues surrounding the prosthesis this 
was recorded. 
For the semi-quantitative analysis, volumes of interests 
(VOIs) were created in each scan at 8 different locations 
around the prosthesis (tip of the prosthesis, femur–prosthesis 
interface, greater and lesser trochanter, neck of the prosthe-
sis, lateral and medial acetabulum, and interface between the 
prosthesis and the median part of the acetabulum). From these 
VOIs the maximum and peak standardized uptake value (SUV 
max and SUVpeak, which are values for the amount of FDG 
uptake) were determined. 
The mean of the SUVmax and SUVpeak at the 8 regions 
was calculated, as a representative of the uptake of the whole 
prosthesis (meanSUVmax and meanSUVpeak). These values 
were corrected for background SUV, using the mean SUV 
(SUVmean) of the liver (meanSUVmax/liver ratio and mean-
SUVpeak/liver ratio). Finally, the correlation of the 4 variables 
between the age of the prosthesis and FDG uptake was deter-
mined.
Statistics
IBM SPSS statistics version 20 (IBM Corp, Armonk, NY, 
USA) was used for statistical analysis. Additionally, StatsDi-
rect version 3 (https://www.statsdirect.co.uk/) was used for 
calculating the confidence intervals (CI) for both the differ-
ence in mean values and the correlation coefficient. Since in 
clinical practice a PJI can occur in any joint prosthesis, regard-
less of the age of the prosthesis, all values were considered 
practically relevant and included in the CI. Continuous vari-
ables were presented as means (SD) or (95% confidence inter-
vals—CI). Not normally distributed data were presented with 
the median and interquartile ranges (IQR) or with the CI of 
the mean. Differences between groups were calculated with 
the Mann–Whitney U-test. Correlation between the age of the 
prosthesis and the SUV uptake was calculated with Spear-
man’s rho. Differences in uptake between the locations were 
calculated with Friedman’s ANOVA. In the case of a statisti-
cally significant result, Wilcoxon’s signed rank test was used 
for post hoc calculation. A p-value < 0.05 was considered sig-
nificant, without correction for multiple comparisons. Effect 
size estimates (r) for Mann–Whitney U and Wilcoxon signed 
rank test was calculated as r = z ⁄ √N (Fritz et al. 2012), with 
z being the standardized test statistics and N the sample size. 
Effect sizes were interpreted as large (> 0.5), medium (0.3–
0.5), and small (< 0.3). Moreover, to overcome the problem 
of correlated observations, additional analyses were done with 
only the last available scan of each patient.
Ethics, funding, and potential conflicts of interest
Ethical permission was acquired for this study from the 
UMCG medical ethical committee on 21 November 2017 
(number M17.221053). None of the authors has had funding 




Finally, 33 patients, with 42 total hip prostheses and 58 FDG-
PET/CT scans, were included (Figure 1). The indication for 37 
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FDG-PET/CT scans was because of a malignancy, the com-
monest being lung carcinoma. In the non-oncological group, 
scans were performed in patients with increased inflammatory 
parameters (n = 8) or other indications (n = 4). Similar FDG 
uptake was found between oncological (meanSUVmax = 2.57 
[IQR 2.08–3.21]) and non-oncological indicated scans (mean-
SUVmax = 3.01 [IQR 2.32–3.95]). 
The cemented group consisted of 38 prostheses scanned 
in 21 patients (median age 73 years [IQR 66–79]). 19 of 
these prostheses were scanned once in 15 different patients. 
7 cemented hip prostheses in 5 patients were scanned twice, 
with a median time between the 2 scans of 1 year (IQR 0.4–
3.9). 1 hip prosthesis was scanned 5 times within a duration of 
approximately 4 years. The uncemented group consisted of 20 
scans from 12 patients (median age 52 years [IQR 50–67]). 9 
patients (11 prostheses) were scanned once. 2 patients with 3 
prostheses were scanned twice (median time between 2 scans: 
0.2 years [IQR 0.1–0.2]), and 1 hip prosthesis in a different 
patient was scanned 3 times within a duration of 9 months.
Visual analysis
Visually, 39/42 prostheses showed uptake of FDG around 
the prosthesis. Diffuse heterogeneous uptake (Figure 2) was 
the most common uptake pattern in both the cemented group 
(32/38) and the uncemented group (16/20) (Table 1). No FDG 
uptake was seen in the periprosthetic soft tissues surrounding 











n = 35 arthroplasties
Excluded (n = 15):
– scan prior to arthroplasty, 5
– revision before scan, 5
– suspected PJI, 1
– suspected looosening, 3
– other reasons, 3
Excluded (n = 31):
– scan prior to arthroplasty, 18
– revision before scan, 2
– suspected PJI, 2
– suspected looosening, 1
– polyarthritis, 3
– other reasons, 5
Excluded (n = 20):
– prosthesis partially scanned, 20
Excluded (n = 8):
– prosthesis partially scanned, 8
Crossmatch
n = 76 arthroplasties
Remaining
n = 45 arthroplasties
n = 58 scans
Remaining
n = 20 arthroplasties
n = 28 scans
Analyzed uncemented 
total hip prostheses
n = 20 scans
Analyzed cemented 
total hip prostheses
n = 38 scans
Figure 1. Flow chart of the patient inclusion process.
Figure 2. Example of 18F-FDG uptake in a non-infected total hip pros-
thesis. (A) Coronal FDG-PET image showing FDG uptake around 
the prosthesis, most prominent at the lateral side of the collum; (B, 
C, D) Coronal fused FDG-PET/CT images at different slices showing 
the uptake around the prosthesis; (E) Transaxial fused FDG-PET/CT 
image showing prominent physiological uptake at the lateral side of 
the cup of the prosthesis.
Table 1. Visual FDG-uptake pattern in non-infected hip prostheses
 Cemented Uncemented
Factor n = 38 n = 20
Diffuse heterogeneous 32 16
Diffuse homogeneous 2 2
Focal 2 0
No uptake 2 2
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Semi-quantitative analysis
The median value of the meanSUVmax in the cemented group 
was 2.7 (CI 2.5–3.1) and in the uncemented group 2.9 (CI 2.7–
4.6) (median difference –0.36 [CI –1.2 to 0.34]). Also, without 
correlated observations the groups were similar. Other vari-
ables did not differ statistically significantly between groups 
either: meanSUVpeak (r = –0.10, p = 0.4), meanSUVmax/liver 
ratio (r = –0.25, p = 0.06), meanSUVpeak/liver ratio (r = –0.26, 
p = 0.05). The background uptake (SUVmean) in the liver was 
for the cemented group 2.9 (IQR 2.6–3.3), for the uncemented 
group 2.7 (IQR 2.3–3.0). The age of the patient did not sta-
tistically significantly influence the FDG uptake in either the 
cemented group (rs = 0.20, p = 0.2) or the uncemented group 
(rs = 0.10, p = 0.7). The SUVmax at the 8 different locations 
around the prosthesis is given in Table 2. The highest uptake 
was observed around the neck of the prosthesis and was signif-
icantly different compared with the other locations in both the 
cemented (r = [range –0.57 to –0.87], p < 0.001) and the unce-
mented group (r = [range –0.74 to –0.88], p < 0.001). Further-
more, other locations with increased uptake were observed at 
the lateral and medial acetabulum and the greater and lesser 
trochanter. The tip of the prosthesis showed minimal uptake. 
In addition, minimal uptake was observed at the femur–pros-
thesis interface of uncemented hip prostheses. FDG uptake 
in this location was absent in 34/38 cemented hip prostheses. 
The uptake between the cemented and uncemented prostheses 
was significantly different at the femur–prosthesis interface 
location (r = –0.37, p = 0.01) (r = –0.29, p = 0.06 without 
correlated observations). FDG uptake at other locations was 
similar between the cemented and uncemented prostheses.
Relation FDG uptake and age of the prosthesis
The median time between the hip arthroplasty and the FDG-
PET/CT scan was 3.9 years (IQR 1.2–9.1) in the cemented 
group and 6.6 years (IQR 1.6–15) in the uncemented group. 
In the cemented group, no relation was found between FDG 
uptake and the age of the prosthesis. However, a moderate 
relationship was found between FDG uptake and the age of 
the prosthesis in the uncemented group (Figure 3). This rela-
tion was observed for all 4 SUV variables (meanSUVmax: rs 
= 0.63 [CI 0.26–0.84], p = 0.003; meanSUVpeak: rs = 0.61 [CI 
0.24–0.83], p = 0.004; meanSUVmax/liver ratio: rs  = 0.63 [CI 
0.26–0.84], p = 0.003; meanSUVpeak/liver ratio: rs  = 0.65 [CI 
0.29–0.85], p = 0.002). This was also observed in the results 
without correlated observations (meanSUVmax: rs  = 0.55, p = 
0.04). The FDG uptake in the uncemented prostheses remains 
stable for the early years, but an increase was observed after 
approximately 13 years.
In general, the cemented total hip prostheses showed a mild 
decline in FDG uptake in the first 5 years after implantation 
(rs = –0.43, p = 0.03 [rs = –0.56, p = 0.05 without correlated 
observations]). After 5 years, the cemented prostheses show a 
relatively stable FDG uptake pattern over time. 
Discussion
The aim of our study was to determine the physiological FDG 
uptake in non-infected total hip prostheses. We found a dif-
fuse heterogeneous uptake pattern in most prostheses with 
median SUVmax values of around 2.5, with the highest uptake 
observed around the neck. FDG uptake was positively related 
with the age of uncemented prostheses, but this finding was 
not observed in cemented prostheses. Our data could aid in the 
development of accurate interpretation criteria for FDG-PET/
CT to diagnose a PJI.
An interesting finding was the increase of FDG uptake with 
time in the uncemented hip prostheses, which was observed 
after approximately 13 years after the primary implant. This 
FDG increase may be due to the development of wear par-
ticles (third particle disease) and/or subtle aseptic loosening, 
although no differences in implant survival between cemented 
and uncemented total hip prosthesis are described in the lit-
erature (Abdulkarim et al. 2013). It is important to note that 
the uncemented prostheses older than 13 years of age all com-
prised one brand of prosthesis: Biomet Mallory Head, a full-
length hydroxyapatite-coated titanium stem combined with an 
uncemented titanium shelled cup. Therefore, we cannot rule 
Figure 3. The relationship between the mean SUVmax and the age of 
the prosthesis in cemented  (left panel) and uncemented hip prosthe-
ses (right panel).
Table 2. SUVmax measured at 8 different locations around the pros-
thesis
 Cemented group Uncemented group 
 Median SUVmax (IQR) Median SUVmax (IQR)
Tip 2.0 (1.6–2.4) 2.2 (1.1–3.1)
Shaft 0.8 (0.6–1.1) 1.1 (0.9–2.0)
Greater trochanter 3.3 (2.5–4.0) 2.2 (1.7–4.2)
Lesser trochanter 2.8 (2.3–3.5) 2.6 (1.7–4.2)
Neck 4.2 (2.9–5.4) 4.6 (3.1–10.4)
Acetabulum lateral 3.1 (2.5–4.4) 3.2 (2.4–6.3)
Acetabulum median 2.0 (1.6–2.6) 1.9 (1.4–3.4)
Acetabulum medial 2.7 (2.0–3.3) 3.2 (2.1–6.5)
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out that the prosthesis design itself, instead of the age of the 
prosthesis, resulted in higher FDG uptake. Unfortunately, we 
do not have data from this type of prosthesis at earlier time 
points. Nevertheless, imaging interpreters should be aware 
that FDG uptake in non-infected older prostheses of this type 
may increase in time and may lead to false-positive results 
regarding diagnosis of a PJI.
Most studies that have been conducted so far on FDG uptake 
in hip prostheses evaluated visual uptake patterns associated 
with loosening or infection. In accordance with our findings, 
these studies concluded that physiological uptake is mostly 
seen around the neck of the prosthesis (Zhuang et al. 2002, 
Vanquickenborne et al. 2003), which theoretically may be 
explained by wear of components and an adverse tissue reac-
tion. In addition, previous studies indicate that an infection 
is highly suspected if there is uptake at the femur–prosthesis 
interface. This finding is also in agreement with our data dem-
onstrating that FDG uptake is almost absent in non-infected 
prostheses (Zhuang et al. 2001, Chacko et al. 2002, Manthey 
et al. 2002). Unlike previous studies, we also observed uptake 
at the lateral and medial acetabulum, which may be due to 
differences in the camera systems that were used. Previous 
studies used an FDG-PET without the addition of a CT scan. 
With the addition of a CT scan, higher resolution images are 
acquired and anatomical structures are better visualized. 
Currently, the interpretation criteria of FDG-PET developed 
by Reinartz et al. (2005) is most often applied. The authors 
conducted a SUVmean analysis on the location with the high-
est uptake found around the prostheses. In that study, the 
SUVmean was 3.3 (SD 1.6) in prostheses without an infection, 
5.0 (SD 3.0) in prostheses with aseptic loosening, and 5.9 (SD 
2.7) in infected prostheses. With this analysis, the SUVmean 
between aseptic loosening and an infected prosthesis was 
similar. Unlike Reinartz et al. (2005), we performed a mean 
SUV analysis at 8 locations around the prosthesis, which may 
improve its diagnostic accuracy. Future studies should address 
the SUV values of these different locations in prostheses with 
aseptic loosening and infection. 
This is the first study that compared the FDG uptake between 
cemented and uncemented hip prostheses and analyzed physi-
ological FDG uptake over time. Furthermore, SUV analyses 
were performed at 8 different locations around the prostheses. 
With this number of locations, a more precise uptake around 
the prosthesis is noted than in previous studies and contributes 
to a better understanding of physiological FDG uptake. Future 
studies should focus on FDG uptake in septic and aseptic loos-
ened total hip prostheses, to further develop adequate inter-
pretation criteria for diagnosing PJI using FDG-PET/CT scan.
In summary, our findings provide insight into the physi-
ological FDG uptake in non-infected total hip prostheses. In 
both cemented and uncemented total hip prostheses a diffuse 
uptake pattern is present with most uptake seen around the 
neck of the prostheses and no uptake in the soft tissues sur-
rounding the prostheses. In addition, the level of FDG uptake 
in non-infected uncemented total hip prostheses is influenced 
by the age and probably the type of prosthesis. These findings 
may aid in the development of accurate interpretation criteria 
for FDG-PET/CT to better differentiate between (physiologi-
cal) reactive inflammation due to a foreign body and a PJI. 
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